Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:

interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC

clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
Clinical Trials Information System (CTIS).

The EU Clinical Trials Register currently displays 44382 clinical trials with a EudraCT protocol, of which 7395 are clinical trials conducted with subjects less than 18 years old. The register also displays information on 18700 older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).

Examples: Cancer AND drug name. Pneumonia AND sponsor name.
How to search [pdf]

Advanced Search:

Search tools

Select Country:	Select Age Range:
Select Trial Status:	Select Trial Phase:
Select Gender:
Select Date Range: to
Select Rare Disease:
IMP with orphan designation in the indication
Orphan Designation Number:
Results Status:
Clear advanced search filters

Trials with a EudraCT protocol (44,382)
Paediatric studies in scope of Art45 of the Paediatric Regulation (18,700)

44,382 result(s) found. Displaying page 1,786 of 2,220.

EudraCT Number: 2020-004784-53

Sponsor Protocol Number: APHP200002

Start Date*: 2022-07-19

Sponsor Name:Assistance Publique - Hôpitaux de Paris

Full Title: Rivaroxaban versus standard of care for patients with excessive atrial ectopy or short atrial runs and high embolism risk SHORT RUN AF

Medical condition: excessive atrial ectopy or short atrial runs and high embolism risk

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	100000004849	10042601	Supraventricular ectopics	LLT

Population Age: Elderly

Gender: Male, Female

Trial protocol: FR (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2017-005082-47	Sponsor Protocol Number: HUS/1209/2017	Start Date*: 2018-09-24
Sponsor Name:Sydän- ja keuhkokeskus, HUS
Full Title: Repolarization study in LQTS patients
Medical condition: Long QT syndrome (LQTS) is a hereditary arrhythmia disease. It causes disturbances to the ion flow through cell membranes of cardiomyocytes. These disturbances can sometimes seen in an electrocardi...
Disease:
Population Age: Adults		Gender: Male, Female
Trial protocol: FI (Completed)
Trial results: (No results available)

EudraCT Number: 2014-003190-42

Sponsor Protocol Number: ANZUP1304

Start Date*: 2014-10-17

Sponsor Name:Cancer Trials Ireland

Full Title: Randomised phase 3 trial of enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer: ENZAMET

Medical condition: Metastatic Prostate Cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10060862	Prostate cancer	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029104	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	SOC

Population Age: Adults, Elderly

Gender: Male

Trial protocol: IE (Trial now transitioned) GB (GB - no longer in EU/EEA)

Trial results: (No results available)

EudraCT Number: 2019-002240-24	Sponsor Protocol Number: SIMASPK01b	Start Date*: 2019-06-27
Sponsor Name:Institut klinické a experimentální medicíny
Full Title: The evolution of advanced microangiopathic diabetic complications before and after simultaneous pancreas and kidney transplantation evaluated with progressive non-invasive methods
Medical condition: Surgical complications (hernia) after simultaneous pancreas and kidney transplantation
Disease:
Population Age: Adults		Gender: Male, Female
Trial protocol: CZ (Trial now transitioned)
Trial results: (No results available)

EudraCT Number: 2021-003179-33

Sponsor Protocol Number: BV-2021/06

Start Date*: 2021-11-29

Sponsor Name:OM Pharma SA

Full Title: A Randomised, Double-Blind, Placebo-controlled, 32-week, Phase IIa trial to investigate the efficacy of OM-85 versus matched placebo in reducing disease severity in children aged 3 to 24 months wit...

Medical condition: Atopic Dermatitis

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	10040785 - Skin and subcutaneous tissue disorders	10012438	Dermatitis atopic	PT

Population Age: Infants and toddlers, Under 18

Gender: Male, Female

Trial protocol: DE (Prematurely Ended) NL (Prematurely Ended) PL (Prematurely Ended) FR (Prematurely Ended)

Trial results: View results

EudraCT Number: 2022-002492-11

Sponsor Protocol Number: PRECESTO

Start Date*: 2023-09-13

Sponsor Name:NFL BIOSCIENCES SA

Full Title: Phase II Study Assessing Efficacy and Safety of NFL-101 on Reduction of Reinforcing Properties of Cigarettes

Medical condition: Tobacco addiction

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	23.0	100000004869	10043905	Tobacco use	HLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: FR (Completed)

Trial results: (No results available)

EudraCT Number: 2022-000366-18

Sponsor Protocol Number: 2020/0420/HP

Start Date*: 2022-08-18

Sponsor Name:CHU de ROUEN

Full Title: Efficacy and Tolerance of Baricitinib, a JAK inhibitor, in the treatment of refractory non-infectious uveitis

Medical condition: Active non-anterior non-infectious uveitis

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	22.1	100000004853	10066681	Acute uveitis	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: FR (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2021-000903-19

Sponsor Protocol Number: UX053-CL101

Start Date*: 2022-08-24

Sponsor Name:Ultragenyx Pharmaceutical Inc.

Full Title: A Phase 1/2 First-in-human, 2-part Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses (Part 1: Open-label) and Repeat Doses (Part 2: Randomized, Double-blind...

Medical condition: Glycogen Storage Disease Type III (GSD III)

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.1	10010331 - Congenital, familial and genetic disorders	10053250	Glycogen storage disease type III	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: FR (Completed) IT (Prematurely Ended) ES (Ongoing)

Trial results: View results

EudraCT Number: 2016-000250-35

Sponsor Protocol Number: WO30070

Start Date*: 2016-06-16

Sponsor Name:Roche Farma, S.A., que representa en España a F. Hoffmann-La Roche Ltd.

Full Title: A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ATEZOLIZUMAB (ANTI?PD-L1 ANTIBODY) IN COMBINATION WITH GEMCITABINE/CARBOPLATIN VERSUS GEMCITABINE/CARBOPLATIN ALONE I...

Medical condition: Urothelial Carcinoma, locally advanced or metastatic

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	19.0	100000004864	10064467	Urothelial carcinoma	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: ES (Ongoing) CZ (Completed) EE (Completed) GR (Completed) PL (Completed) SI (Completed) GB (GB - no longer in EU/EEA) FI (Completed) NL (Completed) PT (Completed) BE (Completed) IT (Completed)

Trial results: View results

EudraCT Number: 2020-003720-16

Sponsor Protocol Number: CMIJ821A12201

Start Date*: 2021-10-15

Sponsor Name:Novartis Pharma AG

Full Title: A double-blind, placebo-controlled, randomized dose-ranging trial to investigate efficacy and safety of intravenous MIJ821 infusion in addition to comprehensive standard of care on the rapid reduct...

Medical condition: Major Depressive Disorder with suicidal ideation with intent

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.1	10037175 - Psychiatric disorders	10057840	Major depression	PT

Population Age: Adults

Gender: Male, Female

Trial protocol: DE (Completed) SK (Prematurely Ended) NL (Prematurely Ended) PL (Prematurely Ended)

Trial results: View results

EudraCT Number: 2017-002707-10

Sponsor Protocol Number: SJ-596

Start Date*: 2018-04-10

Sponsor Name:Regional Dementia Research Centre, Dept of Neurology

Full Title: Serum-monitoring of anti-dementia drugs, and the relevance to side-effects, clinical efficacy and compliance

Medical condition: Dementia in Alzheimers Disease, Parkinsons Disease and Dementia with Lewy Bodies

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10029205 - Nervous system disorders	10012271	Dementia Alzheimer's type	PT
	20.0	10029205 - Nervous system disorders	10012284	Dementia due to Parkinson's disease	LLT
	20.0	10029205 - Nervous system disorders	10067889	Dementia with Lewy bodies	PT
	20.0	10029205 - Nervous system disorders	10075174	Mixed dementia	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DK (Completed)

Trial results: View results

EudraCT Number: 2021-000021-27

Sponsor Protocol Number: ZN-c3-003

Start Date*: Information not available in EudraCT

Sponsor Name:K-Group Beta

Full Title: A Phase 1/2 Dose Escalation and Dose Expansion Study of ZN-c3 in Combination with Gemcitabine in Adult and Pediatric Subjects with Relapsed or Refractory Osteosarcoma

Medical condition: Relapsed or Refractory Osteosarcoma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	100000004864	10039498	Bone sarcomas	HLT

Population Age: Adolescents, Under 18, Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Ongoing) ES (Ongoing) NL (Completed)

Trial results: View results

EudraCT Number: 2016-004347-37	Sponsor Protocol Number: VSV2016b	Start Date*: 2017-01-31
Sponsor Name:Helsinki University Hospital
Full Title: Femoralblock in endovenous laser
Medical condition: venous disease
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: FI (Completed)
Trial results: (No results available)

EudraCT Number: 2021-004891-33	Sponsor Protocol Number: T33/2021	Start Date*: 2022-04-13
Sponsor Name:Turku University Hospital
Full Title: COVID-19 vaccine induced immune response in patients with primary antibody deficiency
Medical condition: COVID-19
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: FI (Completed)
Trial results: (No results available)

EudraCT Number: 2018-000287-29	Sponsor Protocol Number: 1	Start Date*: 2018-03-23
Sponsor Name:Karolinska Institutet
Full Title: Immediate versus delayed insertion of intrauterine contraception at the time of medical abortion An open-label, randomized, multicenter study
Medical condition: Post medical abortion contraception
Disease:
Population Age: Adults		Gender: Female
Trial protocol: SE (Trial now transitioned)
Trial results: (No results available)

EudraCT Number: 2019-003906-28	Sponsor Protocol Number: RC31/17/0447	Start Date*: 2020-02-24
Sponsor Name:CHU de Toulouse
Full Title: Subcutaneous injections of autologous cultured adipose-derived stroma/stem cells to heal refractory ischemic digital ulcers in patients with scleroderma : a phase II study
Medical condition: Patients with systemic sclerosis presenting digital ulcer : - located beyond the proximal interphalangeal joint, on finger surface (included periungueal ulcers), - of ischemic origin according to...
Disease:
Population Age: Adults		Gender: Male, Female
Trial protocol: FR (Trial now transitioned)
Trial results: (No results available)

EudraCT Number: 2020-005007-40

Sponsor Protocol Number: MK-6482-016

Start Date*: 2021-08-10

Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

Full Title: An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Multiple Solid Tumors

Medical condition: HCC, non-microsatellite instability-high (MSI-H)/ deficient mismatch repair (dMMR) CRC, PDAC, and BTC

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.1	100000004864	10065252	Solid tumor	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: NL (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2017-004639-35

Sponsor Protocol Number: 2017/2601

Start Date*: 2018-10-26

Sponsor Name:Gustave Roussy

Full Title: A Phase III trial of acetylsalicylic acid and atorvastatin in patients with castrate-resistant prostate cancer

Medical condition: castrate-resistant prostate cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10076506	Castration-resistant prostate cancer	LLT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10060862	Prostate cancer	PT

Population Age: Adults, Elderly

Gender: Male

Trial protocol: FR (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2020-001985-12

Sponsor Protocol Number: BiCAR

Start Date*: 2021-02-08

Sponsor Name:LYSARC

Full Title: A Phase II Trial Evaluating Glofitamab, a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas after CAR T-cells therapy

Medical condition: Patients who received CAR T-cells therapy for R/R DLBCL (cohort 1) or R/R PMBL, mantle cell lymphoma, t-iNHL or iNHL (cohort 2), at least 1 month ago

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10012822	Diffuse large B-cell lymphoma refractory	PT
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10012821	Diffuse large B-cell lymphoma recurrent	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10026801	Mantle cell lymphoma refractory	PT
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10026800	Mantle cell lymphoma recurrent	PT
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10036714	Primary mediastinal large B-cell lymphoma refractory	PT
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10036713	Primary mediastinal large B-cell lymphoma recurrent	PT
	23.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10065856	Non-Hodgkin's lymphoma unspecified histology indolent	PT
	23.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10061871	Non-Hodgkin's lymphoma transformed recurrent	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: FR (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2021-002369-17	Sponsor Protocol Number: 2021-01	Start Date*: 2021-07-22
Sponsor Name:GETAID
Full Title: Management of moderate POstoperative recurrence in Crohn's disease: a randoMizEd contROLled trial, the POMEROL trial.
Medical condition: Crohn's disease patients having an i2 endoscopic postoperative recurrence 6-12 months after ileocolonic anastomosis.
Disease:
Population Age: Adults		Gender: Male, Female
Trial protocol: FR (Trial now transitioned)
Trial results: (No results available)

Subscribe to this Search
To subscribe to the RSS feed for this search click here

. This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.

Download Options:
Number of Trials to download:

Download Content:

Download Format:


Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.

Query did not match any studies.

For support, Contact us.

The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

European Medicines Agency © 1995-Mon Mar 09 06:41:00 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
United Kingdom
Outside EU/EEA